Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Use Tarceva (Erlotinib) with Caution in Patients with Liver Problems
Based on new safety information, the manufacturers OSI and Genentech are warning that TARCEVA (erlotinib) should be used with extra caution in patients with advanced cancer with liver involvement and in patients with a history of liver problems from other causes. Tarceva is approved for the treatment of patients with advanced non-small cell lung cancer after failure of at least one other chemotherapy regimen. Tarceva is also approved for use with gemcitabine for the treatment of patients with pancreatic cancer. For more information please visit: http://www.fda.gov/medwatch/safety/2008/safety08.htm#Tarceva
Learn More

FDA Stops Imports of Ranbaxy Products
The U.S. Food and Drug Administration (FDA) is stopping the importation of several drug products produced by the generic drug manufacturer Ranbaxy Laboratories, Ltd.  The FDA is concerned that Ranbaxy facilities in India are not following U.S. standards for good manufacturing practices.  Although acyclovir is one of the medications manufactured by Ranbaxy, drug shortages are not expected because, in most instances, there are enough other suppliers that can help meet demand for acyclovir. For more information, please visit: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116949.htm
Learn More